Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 7Tumor-Agnostic 3Gastrointestinal 3Breast 3Other solid neoplasm 2Head & Neck 2Gynecologic 2Other hematologic neoplasm 1Genitourinary 1Dermatologic 1CNS 1

Conditions

Prostatic Neoplasms 1

Interventions

Prednisone 122Docetaxel 118enzalutamide 101pembrolizumab 96Sunitinib 86Leuprolide 84Abiraterone Acetate 83Nivolumab 78Gemcitabine 76bicalutamide 54Radiotherapy 54Goserelin 54Bevacizumab 54Cisplatin 52Magnetic Resonance Spectroscopy 49Everolimus 49acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 46Sorafenib 40Carboplatin 40Paclitaxel 37Radiosurgery 36atezolizumab 35abiraterone 33pazopanib 32cabozantinib 32Ipilimumab 32Axitinib 30Cyclophosphamide 29Androgen Antagonists 29Radiation 28

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × bintrafusp alfa protein, human × Genitourinary × Clear all
NCT03493945 2025-09-30

Phase I/II Study of Immunotherapy Combination BN-Brachyury Vaccine, M7824, N-803 and Epacadostat (QuEST1)

National Institutes of Health Clinical Center (CC)

Phase 1/2 Completed
59 enrolled 20 charts
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡